Eagle Pharmaceuticals (EGRX) News Today $0.55 -0.05 (-8.33%) (As of 12/20/2024 04:19 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Eagle Pharmaceuticals to Delist from NasdaqNovember 19, 2024 | investing.comEagle Announces Update on Delisting from Nasdaq and SEC DeregistrationNovember 15, 2024 | globenewswire.comEagle Pharmaceuticals Appoints New CFO Amid Leadership ChangeNovember 12, 2024 | markets.businessinsider.comEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNovember 1, 2024 | finanznachrichten.deEagle Pharmaceuticals Implements Stockholder Rights PlanNovember 1, 2024 | markets.businessinsider.comEagle Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanOctober 31, 2024 | markets.businessinsider.comUnion Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals SharesOctober 8, 2024 | gurufocus.comEagle Pharmaceuticals (NASDAQ:EGRX) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.com173,365 Shares in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Bought by Perceptive Advisors LLCPerceptive Advisors LLC acquired a new position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 173,365 shares of the specialty pharmaceutical company's stock, valued at approxiSeptember 30, 2024 | marketbeat.comEagle Pharmaceuticals IncSeptember 28, 2024 | money.usnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.comStockNews.com assumed coverage on shares of Eagle Pharmaceuticals in a research note on Thursday. They set a "hold" rating for the company.September 26, 2024 | marketbeat.comIs Eagle Materials Inc. (EXP) the Best Stock Pick You Need to Know in Jim Cramer’s Latest Watchlist?September 15, 2024 | msn.comEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Short Interest UpdateEagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Get Free Report) was the target of a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 484,200 shares, a growth of 14.1% from the July 31st total of 424,400 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 158,000 shares, the days-to-cover ratio is currently 3.1 days.August 31, 2024 | marketbeat.comEagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqAugust 27, 2024 | globenewswire.comEagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Crosses Below Two Hundred Day Moving Average of $4.98Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Cross Below 200-Day Moving Average of $4.98August 17, 2024 | marketbeat.comEagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.comStockNews.com started coverage on shares of Eagle Pharmaceuticals in a report on Saturday. They issued a "hold" rating for the company.August 17, 2024 | marketbeat.comAcadian Asset Management LLC Sells 235,109 Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)Acadian Asset Management LLC reduced its position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Free Report) by 81.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 52,446 shares of theJuly 29, 2024 | marketbeat.comEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Sees Large Decline in Short InterestEagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Get Free Report) saw a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 994,400 shares, a drop of 7.9% from the May 31st total of 1,080,000 shares. Approximately 8.7% of the company's shares are sold short. Based on an average daily volume of 149,300 shares, the short-interest ratio is presently 6.7 days.July 4, 2024 | marketbeat.comEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Sees Significant Decrease in Short InterestEagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Get Free Report) saw a significant drop in short interest in May. As of May 31st, there was short interest totalling 1,080,000 shares, a drop of 5.3% from the May 15th total of 1,140,000 shares. Based on an average daily trading volume, of 151,900 shares, the short-interest ratio is presently 7.1 days. Currently, 9.5% of the company's stock are short sold.June 18, 2024 | marketbeat.comEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 22, 2024 | finanznachrichten.deEagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 22, 2024 | globenewswire.comBrandes Investment Partners LP Lowers Stock Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)Brandes Investment Partners LP reduced its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Free Report) by 34.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 745,080 shares of the specialty pharmaceutical company's stMay 21, 2024 | marketbeat.comEagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual MeetingApril 30, 2024 | finance.yahoo.comEagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, FloridaApril 15, 2024 | globenewswire.comEagle Pharmaceuticals faces potential Nasdaq delistingApril 14, 2024 | investing.comStocks Slightly Higher as US Mar PPI Climbs Less Than ExpectedApril 13, 2024 | msn.comStocks Mixed as Bond Yields ClimbApril 13, 2024 | msn.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KApril 12, 2024 | finance.yahoo.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KApril 12, 2024 | globenewswire.comEagle Pharmaceuticals to cut 36% of workforceFebruary 29, 2024 | msn.comEagle Pharmaceuticals Stock (NASDAQ:EGRX), Short Interest ReportFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comBrandes Investment Partners LP Boosts Stock Holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)Brandes Investment Partners LP grew its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Free Report) by 34.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,134,363 shares of the specialty pharmacFebruary 19, 2024 | marketbeat.comEAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their OptionsFebruary 9, 2024 | prnewswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)February 8, 2024 | stockhouse.comLevi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming DeadlineFebruary 8, 2024 | markets.businessinsider.comShareholders that lost money on Eagle Pharmaceuticals, Inc.(EGRX) should contact Levi & Korsinsky about pending Class Action - EGRXFebruary 8, 2024 | markets.businessinsider.comClass Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) Seeking Recovery for Investors - Contact Levi & KorsinskyFebruary 7, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming DeadlineFebruary 6, 2024 | stockhouse.com7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 2, 2024 | stockhouse.comEGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm!February 2, 2024 | barrons.comAssenagon Asset Management S.A. Has $3.43 Million Stock Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)Assenagon Asset Management S.A. raised its position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX - Free Report) by 66.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 217,February 2, 2024 | marketbeat.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 1, 2024 | stockhouse.comEagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Passes Below Two Hundred Day Moving Average of $12.10Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below Two Hundred Day Moving Average of $12.10February 1, 2024 | marketbeat.comEGRX 9-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities...February 1, 2024 | markets.businessinsider.comINVESTOR ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - EGRXJanuary 31, 2024 | stockhouse.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 31, 2024 | barrons.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 30, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming DeadlineJanuary 30, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRXJanuary 28, 2024 | stockhouse.com Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode. >> Register for the Workshop Now EGRX Media Mentions By Week EGRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EGRX News Sentiment▼0.000.60▲Average Medical News Sentiment EGRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EGRX Articles This Week▼01▲EGRX Articles Average Week Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LEXX News VYNE News ATNM News OCX News LTRN News ELEV News LUMO News MRKR News CALC News TPST News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EGRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
